Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Durvalumab Monotherapy	374
Overall Study	STARTED	Durvalumab + Tremelimumab	372
Overall Study	STARTED	SoC Chemotherapy	372
Overall Study	Received Treatment	Durvalumab Monotherapy	369
Overall Study	Received Treatment	Durvalumab + Tremelimumab	371
Overall Study	Received Treatment	SoC Chemotherapy	352
Overall Study	COMPLETED	Durvalumab Monotherapy	0
Overall Study	COMPLETED	Durvalumab + Tremelimumab	0
Overall Study	COMPLETED	SoC Chemotherapy	0
Overall Study	NOT COMPLETED	Durvalumab Monotherapy	374
Overall Study	NOT COMPLETED	Durvalumab + Tremelimumab	372
Overall Study	NOT COMPLETED	SoC Chemotherapy	372

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02453282/flow